Cargando…

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer

Androgen deprivation therapy is the mainstay of treatment of advanced prostate cancer (PCa). However, a significant portion of patients experience disease relapse and tumors ultimately evolve into castration resistant prostate cancer (CRPC), for which there is no cure in the clinic. The Polycomb pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Changping, Jin, Xin, Yang, Jing, Yang, Yinhui, He, Yundong, Ding, Liya, Pan, Yunqian, Chen, Shuai, Jiang, Jingting, Huang, Haojie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823118/ https://www.ncbi.nlm.nih.gov/pubmed/26657505 http://dx.doi.org/10.18632/oncotarget.6497

Ejemplares similares

LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer
por: Wang, Dejie, et al.
Publicado: (2015)

Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer
por: Ma, Linlin, et al.
Publicado: (2019)

Polycomb-independent activity of EZH2 in castration resistant prostate cancer
por: Xu, Kexin, et al.
Publicado: (2013)

Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
por: Coulter, Jonathan B., et al.
Publicado: (2023)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC
por: Schade, Amy E., et al.
Publicado: (2023)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
por: Labaf, Maryam, et al.
Publicado: (2022)

Prognostic evaluation of pancreatic cancer based on the model of chemo-radiotherapy resistance-related genes
por: Sun, Hui, et al.
Publicado: (2023)

Ilicicolin A Exerts Antitumor Effect in Castration-Resistant Prostate Cancer Via Suppressing EZH2 Signaling Pathway
por: Guo, Lang, et al.
Publicado: (2021)

P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth
por: Gang, Xiaokun, et al.
Publicado: (2016)

Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
por: Katano, Atsuto, et al.
Publicado: (2021)

Novel agents in the management of castration resistant prostate cancer
por: Chaturvedi, Shruti, et al.
Publicado: (2014)

RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis
por: Bai, Yang, et al.
Publicado: (2019)

Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122
por: Cong, Xiaonan, et al.
Publicado: (2021)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
por: Asowed, Mustafa, et al.
Publicado: (2023)

Concurrent chemo-radiotherapy with proton therapy: reduced toxicity with comparable oncological outcomes vs photon chemo-radiotherapy
por: Baumann, Brian C., et al.
Publicado: (2020)

Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma
por: Song, Xing, et al.
Publicado: (2018)

Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy
por: Wu, Xiaoning, et al.
Publicado: (2019)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Outcome of (177)Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2021)

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
por: Liu, Yang, et al.
Publicado: (2021)

Phytochemicals as Chemo-Preventive Agents and Signaling Molecule Modulators: Current Role in Cancer Therapeutics and Inflammation
por: Ahmed, Muhammad Bilal, et al.
Publicado: (2022)

Fasting Enhances the Response of Glioma to Chemo- and Radiotherapy
por: Safdie, Fernando, et al.
Publicado: (2012)

EZH2 takes the stage when BRCA1 loses
por: Wang, Lan, et al.
Publicado: (2013)

The Role of Isothiocyanates as Cancer Chemo-Preventive, Chemo-Therapeutic and Anti-Melanoma Agents
por: Mitsiogianni, Melina, et al.
Publicado: (2019)

Unveiling the non-canonical functions of EZH2 in prostate cancer
por: Yi, Yang, et al.
Publicado: (2023)

Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer
por: Johnson, James K., et al.
Publicado: (2016)

Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer
por: Myung, Jae-Kyung, et al.
Publicado: (2017)

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
por: Westdorp, Harm, et al.
Publicado: (2019)

Dual inhibition of AKT‐mTOR and AR signaling by targeting HDAC3 in PTEN‐ or SPOP‐mutated prostate cancer
por: Yan, Yuqian, et al.
Publicado: (2018)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

Stereotactic ablative body radiotherapy for oligometastatic inguinal lymph node in castrate resistant prostate cancer
por: Goyal, Shikha, et al.
Publicado: (2023)

Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
por: He, Yundong, et al.
Publicado: (2016)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
por: Henriquez, Ivan, et al.
Publicado: (2021)

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
por: Hu, Jason, et al.
Publicado: (2022)

Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma
por: Matsui, Jennifer K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h2rsvdmddcr75ujsovinbhv6ti